Calliditas Therapeutics AB (NAS:CALT)
$ 22 0 (0%) Market Cap: 590.48 Mil Enterprise Value: 589.81 Mil PE Ratio: 0 PB Ratio: 18.64 GF Score: 49/100

Calliditas Therapeutics AB (publ) - Special Call Transcript

Nov 09, 2020 / 01:30PM GMT
Release Date Price: $33.95 (+34.88%)
Operator

Hello, and welcome to Calliditas press conference. (Operator Instructions) Today, I'm pleased to present CEO, Renee Lucander; and CMO, Richard Philipson. Speakers, please begin.

Renee Aguiar;Lucander;publ;CEO
Calliditas Therapeutics AB

()-

Thank you. So I'm delighted to welcome you to this presentation of the Phase III Part A top line data readout of the trial NefIgArd.

If you turn to Page 3, I'm just going to give a very brief summary before I hand over to our CMO to take you through the data. Just to remind you, the company is listed both in Sweden and the U.S. on OMX and on Nasdaq. We listed in Sweden in 2018 and recently listed on Nasdaq in the U.S. in June of this year. Our lead candidate, Nefecon, is a novel investigational treatment for IgAN, and that locally treats this disease with a view to be disease modifying. And we do this by locally treating a big presumed origin of this disease.

In terms of the company's position, we are now positioned clearly to be the first potentially

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot